---
title: "Zhejiang Medicine: Plans to repurchase company shares for 100 million to 200 million yuan, with a repurchase price not exceeding 20.83 yuan per share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236542922.md"
description: "On April 18th, ZMC announced that it plans to repurchase company shares through centralized bidding, with a total repurchase amount of no less than RMB 100 million and no more than RMB 200 million. The repurchase price will not exceed RMB 20.83 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan"
datetime: "2025-04-18T08:34:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236542922.md)
  - [en](https://longbridge.com/en/news/236542922.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236542922.md)
generator: "portal-rs"
---

# Zhejiang Medicine: Plans to repurchase company shares for 100 million to 200 million yuan, with a repurchase price not exceeding 20.83 yuan per share

On April 18th, ZMC announced that it plans to repurchase company shares through centralized bidding, with a total repurchase amount of no less than RMB 100 million and no more than RMB 200 million. The repurchase price will not exceed RMB 20.83 per share. The repurchased shares will be used for employee stock ownership plans or equity incentives. The repurchase period is within 12 months from the date the board of directors approves the share repurchase plan

### Related Stocks

- [600216.CN](https://longbridge.com/en/quote/600216.CN.md)

## Related News & Research

- [Fed Chair Warsh Told Markets to Read Data. They Read Him Instead.](https://longbridge.com/en/news/298030286.md)
- [Manufacturers are getting frustrated: 'The economy is annoying'](https://longbridge.com/en/news/297685808.md)
- [Manufacturers are getting frustrated: 'The economy is annoying'](https://longbridge.com/en/news/297686341.md)
- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**